The Lancet Conference Alerts | Read our late-breaking content from BTS Winter Meeting 2025 +++...

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext?dgcid=hubspot_email_conferencealerts_bts25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9xgpp1L9ANpjtX4zNDGMGdHCP0E_P557ZcGWVvRN0zGajf0K1q9H0Rf2_XLr6ge1QnmX0VkHKlaMoof-oPtXATeRW1Rg&_hsmi=391783220&utm_content=391783220&utm_source=hs_email COMMENTS Efficacy of tezepelumab in reducing oral corticosteroid use in severe asthma Free with registration until Dec 6, 2025 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00395-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_bts25&_hsenc=p2ANqtz-9N7YZ8Lglfwh-drZfqh25_nsTIpx7dq0iVjZTmiWUXxM04EMO2FucYIhvycuDm46NYNEVEB21_vD_LbgIdL-la-xzAaA&_hsmi=391783220&utm_content=391783220&utm_source=hs_email November 27, 2025 Comment Time to pull the plug on subglottic secretion drainage? Michael Klompas,Richard Branson https://www.thelancet.com/journals/lanres/onlinefirst